Active Ingredient History

  • Now
Alvocidib is a flavonoid alkaloid CDK9 kinase inhibitor under clinical development by Tolero Pharmaceuticals for the treatment of acute myeloid leukemia. It has been studied also for the treatment of arthritis and atherosclerotic plaque formation. The target of alvocidib is the positive transcription elongation factor P-TEFb. Treatment of cells with alvocidib leads to inhibition of P-TEFb and the loss of mRNA production.   Wikipedia

  • SMILES: CN1CC[C@@H]([C@H](O)C1)c2c(O)cc(O)c3C(=O)C=C(Oc23)c4ccccc4Cl
  • Mol. Mass: 401.85
  • ALogP: 3.3
  • ChEMBL Molecules:
More Chemistry
alvocidib | alvocidib freebase | alvocidib hcl | alvocidib hydrochloride | (-)cis-5,7-dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4h-1-benzopyran-4-one | flavopiridol | flavopiridol hcl | hl-275 | hmr 1275 | hmr-1275 | l 868275 | l-868275 | l-86-8275 | l86-8275 | mdl-107826a | nsc-649890


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue